HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.

Abstract
Hemi-synthetic derivatives of glycopeptides have demonstrated bactericidal activity towards Gram-positive bacteria, including vancomycin-resistant strains (oritavancin and telavancin), and a prolonged half-life, allowing for once-daily (oritavancin and telavancin) or once-weekly (dalbavancin) administration. These compounds have proved effective for the treatment of infections caused by multidrug-resistant Gram-positive bacteria, including complicated skin and skin structure infections (oritavancin, telavancin and dalbavancin), bacteremia (oritavancin and dalbavancin) and nosocomial pneumonia. This review compares the antibacterial activity and clinical activity of three glycopeptides, oritavancin, telavancin and dalbavancin, and the natural lipoglycopeptide, ramoplanin, which, being unstable in the bloodstream, is administered orally to treat Clostridium difficile colitis and for digestive tract decontamination. All of these compounds, with the exception of oritavancin, have received Fast Track designation from the FDA because of their clinical efficacy.
AuthorsFrançoise Van Bambeke
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 8 Pg. 740-9 (Aug 2006) ISSN: 1472-4472 [Print] England
PMID16955686 (Publication Type: Journal Article, Review)
Chemical References
  • Aminoglycosides
  • Anti-Bacterial Agents
  • Depsipeptides
  • Glycopeptides
  • Teicoplanin
  • ramoplanin
  • dalbavancin
  • oritavancin
  • telavancin
Topics
  • Aminoglycosides (pharmacology)
  • Anti-Bacterial Agents (pharmacokinetics, pharmacology)
  • Depsipeptides (pharmacokinetics, pharmacology)
  • Glycopeptides (pharmacokinetics, pharmacology)
  • Gram-Positive Bacteria (drug effects)
  • Humans
  • Teicoplanin (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: